DIRAS family GTPase 1Genealiases: Di-Ras1 · GBTS1 · RIG
Q-omics provides the consensus-scored DIRAS1 profile across patient tissues and cancer cell-line models. DIRAS1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DIRAS1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, DIRAS1 RNA expression shows 17,693 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where DIRAS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DIRAS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DIRAS1 survival associations across molecular data types. DIRAS1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DIRAS1 RNA expression–survival associations across cancer types. High DIRAS1 expression shows unfavorable associations in UVM, LUSC, KIRC, BLCA and UCS, but favorable associations in PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DIRAS1 RNA expression.
This table summarizes DIRAS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DIRAS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DIRAS1 shows lower tumor expression in KIRC, COAD and HNSC and higher tumor expression in LUAD, LIHC and THCA. The KIRC box plot shows higher DIRAS1 RNA expression in normal versus tumor tissue (log2 FC = −2.996, t-test p < 0.001).
This table shows molecular features associated with DIRAS1 in patient tissues and cancer cell lines. In patient samples, DIRAS1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DIRAS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
